AI Stock Recent News Arlington Asset Investment Corp (AI) 27.29

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Arlington Asset Investment Corp (AI) 27.29 $AI

E*TRADE (ETFC) Lowers Corporate Debt, Prices Notes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:50PM CST
On Nov 12, E*TRADE (ETFC), the online brokerage firm, unveiled its debt restructuring plans.
GS: 189.98 (-0.26), PJC: 57.54 (-0.03), ETFC: 23.19 (+0.04), AI: 27.29 (+0.06)

3 Buy-Rated Dividend Stocks Taking The Lead: AI, CTL, O
at The Street - Fri Nov 07, 9:30AM CST
These 3 dividend stocks are rated a Buy by TheStreet
AI: 27.29 (+0.06), O: 45.70 (-0.47), CTL: 40.79 (-0.13)

Investment Technology Group (ITG) Jumps: Stock Rises 7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 8:32AM CST
Investment Technology Group Inc. (ITG) was a big mover last session, as the company saw its shares rise nearly 7% on the day.
ITG: 19.51 (+0.07), PJC: 57.54 (-0.03), AI: 27.29 (+0.06), BGCP: 8.56 (-0.02)

Interactive Brokers' October Metrics Up, Trades Improve - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 5:10PM CST
Interactive Brokers' (IBKR) Electronic Brokerage segment recorded a year-over-year as well as sequential increase in brokerage metrics for Oct 2014.
IBKR: 27.14 (+0.22), AI: 27.29 (+0.06), FXCM: 16.66 (+0.06), BGCP: 8.56 (-0.02)

Quanta Raises £27 Million to Prepare its Advanced Haemodialysis System SC+ for Launch
PR Newswire - Mon Nov 03, 1:00AM CST
~ Funding Round Led by ALIAD the Venture Vehicle of Air Liquide ~
IMI: 2.30 (+0.13), AI: 27.29 (+0.06)

Arlington Asset Investment's (AI) CEO Rock Tonkel on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Oct 28, 12:06PM CDT

AI: 27.29 (+0.06)

JMP Group (JMP) in Focus: Stock Adds 6.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 7:37AM CDT
JMP Group Inc. (JMP) was a big mover last session, as the company saw its shares rise nearly 7% on the day.
JMP: 7.37 (-0.18), AI: 27.29 (+0.06), FXCM: 16.66 (+0.06), BGCP: 8.56 (-0.02)

Arlington puts money to work; beats esimates
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 8:11PM CDT

AI: 27.29 (+0.06)

More on Arlington Asset Investment Q3 results
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 4:43PM CDT

AI: 27.29 (+0.06)

Arlington Asset Investment beats by $0.21, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 4:25PM CDT

AI: 27.29 (+0.06)

Arlington Asset Investment Corp. Reports Third Quarter 2014 Financial Results
PR Newswire - Mon Oct 27, 4:23PM CDT
Arlington Asset Investment Corp. (NYSE: AI) (the "Company" today reported non-GAAP core operating income of $28.7 million for the quarter ended September 30, 2014, or $1.36 per share (diluted). A reconciliation of non-GAAP core operating income to GAAP net income appears at the end of this press release. On a GAAP basis, the Company reported net income of $12.8 million for the quarter ended September 30, 2014, or $0.61 per share (diluted), compared to net income of $18.8 million for the quarter ended June 30, 2014, or $0.94 per share (diluted), and net income of $3.1 million, or $0.18 per share (diluted), for the quarter ended September 30, 2013.
AI: 27.29 (+0.06)

Should You Buy Arlington Asset Investment (AI) Ahead of Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 7:57AM CDT
Arlington Asset Investment is seeing favorable earnings estimate revision activity and an earnings beat might be in the cards for the upcoming report.
AI: 27.29 (+0.06)

Arlington Asset Investment Corp. to Report Third Quarter 2014 Financial Results
PR Newswire - Wed Oct 22, 3:45PM CDT
Arlington Asset Investment Corp. (NYSE: AI) (the "Company" announced today that the Company will release results for the quarter ended September 30, 2014 after the market closes on Monday, October 27, 2014, and will hold a conference call for investors at 9:00 A.M. Eastern Time on Tuesday, October 28, 2014 to discuss the results.
AI: 27.29 (+0.06)

Interpublic Q3 Adjusted Earnings In Line, Revenues Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 11:10AM CDT
Interpublic (IPG) reported third-quarter 2014 earnings of 21 cents per share, up 23.5% from 17 cents per share in the year-ago quarter and in line with the Zacks Consensus Estimate.
CACI: 86.08 (-0.24), IPG: 19.44 (+0.03), AGNC: 22.87 (+0.20), AI: 27.29 (+0.06)

Will Northern Trust (NTRS) Miss Earnings This Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 4:20PM CDT
Northern Trust Corporation (NTRS) is scheduled to report its third-quarter 2014 results on Wednesday, Oct 22
NTRS: 67.79 (+0.27), AI: 27.29 (+0.06), WRLD: 77.12 (-0.08), CIT: 48.98 (-0.29)

Will T. Rowe Price (TROW) Earnings Surprise This Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 4:00PM CDT
T. Rowe Price Group, Inc. (TROW) is scheduled to report third-quarter 2014 results before the opening bell on Thursday, Oct 23.
TROW: 82.12 (-0.55), AI: 27.29 (+0.06), GCAP: 8.97 (+0.03), CIT: 48.98 (-0.29)

Will 3M (MMM) Miss on Q3 Earnings Despite Key Focus? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 3:00PM CDT
3M Company (MMM) is scheduled to report its third-quarter 2014 results before the opening bell on Oct 23.
AEP: 56.06 (-0.25), MMM: 158.85 (+0.50), AI: 27.29 (+0.06), ALL: 66.58 (-0.34)

Will Janus Capital (JNS) Disappoint this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 2:50PM CDT
Janus Capital Group, Inc. (JNS) is scheduled to report its third-quarter 2014 results on Thursday, Oct 23, before the market opens
JNS: 14.63 (-0.03), AI: 27.29 (+0.06), WRLD: 77.12 (-0.08), CIT: 48.98 (-0.29)

Can Hudson City Beat Q3 Earnings on Low Interest Expenses? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 11:20AM CDT
We expect Hudson City (HCBK) to beat earnings when it reports third-quarter 2014 results on Oct 22, before the market opens.
ALLY: 23.46 (+0.26), AI: 27.29 (+0.06), CIT: 48.98 (-0.29), HCBK: 9.82 (-0.05)

Is Sallie Mae (SLM) Likely to Miss Earnings This Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 12:40PM CDT
Sallie Mae (SLM) is scheduled to report its third-quarter 2014 results on Wednesday, Oct 22, after market close.
SLM: 9.86 (-0.10), AI: 27.29 (+0.06), WRLD: 77.12 (-0.08), CIT: 48.98 (-0.29)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 14

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 13

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 14

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 9

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 14

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 15

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 14

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 11

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 8

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Telehealth Trends: A Comprehensive Yearly Insight

Updated Category News Views 346

FAIR Health's Telehealth Tracker: A Milestone Year FAIR Health has reached a significant milestone with its Monthly Telehealth Regional Tracker entering its sixth year. This tracker provides valuable insights into how telehealth usage has evolved, empowering stakeholders to understand trends in healthcare delivery. New Features and Data Insights The latest iteration of...

Continue Reading
Exploring Analog Devices: A $1000 Investment Journey

Updated Category News Views 139

The Growth of Analog Devices Inc (NASDAQ: ADI) Investors have increasingly turned their attention to Analog Devices Inc, a leader in the semiconductor industry. Over the last five years, Analog Devices has consistently outperformed the market, showcasing an annualized return of 16.0%. With a current market capitalization standing at an impressive $119.42 billion, the...

Continue Reading
Celebrating Excellence in Clinical Simulation: Meet the Nominees

Updated Category News Views 110

Highlighting Excellence in Clinical Simulation Awards A Representation of the Best in Simulation Healthcare Education in 2024 Education Management Solutions (EMS), a frontrunner in healthcare simulation and competency management platforms, has proudly announced its nominees for the 16th Annual Excellence in Clinical Simulation Awards. Each year, this noteworthy event...

Continue Reading
Significant Oil Price Drop Benefits Airlines and Cruise Lines

Updated Category News Views 195

Oil Prices Experience a Significant Drop Amid Easing Tensions Oil prices witnessed a noticeable decrease recently, plummeting over 5% during early trading in New York. This shift came as geopolitical tensions in the Middle East appeared to stabilize after an assurance from Israeli Prime Minister Benjamin Netanyahu that Iran’s oil facilities would not be targets in any...

Continue Reading
RxSight, Inc. Faces Legal Challenges: Investors Invited to Join Lawsuit

Updated Category News Views 136

RxSight, Inc. Investors Invited to Participate in Class Action Lawsuit Investors of RxSight, Inc. are becoming aware of significant opportunities to engage in a class action lawsuit. This legal action is being initiated by Bronstein, Gewirtz & Grossman, LLC, a law firm with a national reputation for advocating on behalf of investors. They are notifying shareholders that...

Continue Reading